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Background: The purpose of this study was to investigate the clinical efficacy of extended resection with
osteotomy, fenestration and conservation of muscle (tendon) insertion in the treatment of bone tumors.
Methods: A total of 15 patients with locally aggressive bone tumors (Enneking stage II) in the adjacent muscle
(tendon) insertion of the proximal extremity were enrolled in the present study (mean age of 29 years). Extended
curettage of lesions with osteotomy, fenestration and/or conservation of muscle (tendon) insertion and internal
fixation with a bone graft or bone cement was performed at stage I. Postsurgical brace protection was used for
4 to 12 weeks and the patients were periodically followed-up by X-ray and functional assessment. Recurrence,
postsurgical Enneking score and outcome rating were assessed.
Results: Treated cases included 15 patients aged 29 ±7.75 years (range, 18 to 42) with a male to female ratio of 8:7.
Six had a femoral tumor and nine had a humeral tumor. These tumors comprised three chondroblastomas, five
giant-cell tumors and seven aneurysmal bone cysts. Follow-up for 48 ±12.95 months (range, 25 to 72) revealed that
13 of 15 (87%) patients exhibited no recurrence. Local recurrence was observed in a patient with an aneurysmal
bone cyst (nine months) and one with a giant-cell tumor (12 months). Mean Enneking scores were 27 ±4.07
(range, 18 to 29). Except for the patient with the recurrent giant-cell tumor, all patients reported good (13%,
2 out of 15) or very good (80%, 12 out of 15) outcomes. Very good outcomes were reported in 92% of patients
(12 out of 13) without recurrence.
Conclusions: The procedures used in this study achieved high clinical efficacy, complete lesion removal, reduced
recurrence and good restoration of joint function in patients with primary locally aggressive Enneking stage II bone
tumors of the proximal extremities.
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Locally aggressive bone tumors are a group of com-
monly recurrent and metastatic bone tumors that
predominantly occur in the epiphysis of the long bone of
the adjacent joints, including giant-cell tumor (GCT) of
bone, aneurysmal bone cyst (ABC), chondroblastoma
(CBT) and osteoblastoma [1]. According to Enneking
surgical staging, progression of these tumors can be
understood in terms of tumor stage [2]. Using this scale,
stage I represents the latent phase. At stage II, tumors
become active, exhibiting expansive growth and thinning
of the bone cortex within the compartment. Stage III is
the most aggressive, with lesions piercing through the
bone cortex and involving soft tissues surrounding the
compartment. Routine treatment includes surgical ther-
apy with extended curettage (IC) of lesions, local adju-
vant treatment, graft implantation and effective internal
fixation [1]. Because most lesions are adjacent to the
joint and muscle (tendon) insertion, IC of lesions may
damage muscle (tendon) insertions, exerting detrimental
effects on postsurgical limb function. If protection is
limited to the muscle (tendon) insertion, a sufficient
operative field is difficult to obtain, preventing effective
curettage. Therefore, improved methods for treatment
selection are required for more effective and successful
treatment of locally aggressive musculoskeletal tumors.
The current status of treatment and recurrence of these
tumors, as discussed in the present study, are briefly
reviewed.
Treatment of aneurysmal bone cysts
ABCs are relatively rare in primary bone tumors,
constituting only 1% to 2% of all primary bone tumors.
These tumors exhibit rapid growth and high invasive-
ness, and are often destructive to surrounding tissues
[3]. Ubiquitin-specific protease 6 has been implicated in
the development of ABCs [3,4], and treatment with
curettage and bone grafting or bone cementation has
been reported to achieve 70% to 90% success with 10%
to 30% recurrence rates [3,5]. IC, or aggressive curettage,
applies drills, local adjuvant therapies (such as caute-
rization), phenolic therapies or cryotherapies to reduce
the rate of local recurrence [3,5,6]. ABCs of specific
sites, such as the vertebral body and pelvis, can be
treated with sclerosing therapies using percutaneous
injections of Ethibloc, ethanol and methylprednisolone.
In addition, selective arterial embolization has been re-
commended as an alternative therapy [7].
Treatment of chondroblastomas
A CBT is a rare cartilage-derived bone tumor that consti-
tutes 1% of all benign bone tumors. It predominantly
affects young men and often exhibits invasiveness or ma-
lignant behavior [8,9]. Following recommended surgicaltreatments, the two- to three-year recurrence rate is as
high as 10% to 20%, which may partially be due to wide
application of inappropriate surgical methods [9,10]. IC,
however, has been demonstrated to reduce local recur-
rence rates [9-11]. IC has been employed for the treatment
of bone CBT, producing a recurrence rate of only 11%
(2 out of 18) in one study [11]. In another study of 25
patients with a CBT, IC produced a recurrence rate
of only 4.2% (1 out of 24) over an eight-year follow-
up period [8].
Treatment of giant-cell tumors of bone
GCTs of bone constitute 4% to 8% of all primary bone
tumors and predominantly occur in 20- to 40-year-old
(middle-aged) individuals [12]. Recently, biotherapy with
receptor activator of nuclear factor kappa-B ligand mono-
clonal antibodies and colony-stimulating factor 1 signaling
pathway inhibitor has been introduced for clinical treat-
ment of GCT [13], though optimal clinical treatment still
depends on surgery. Conventional intralesional curettage
has been reported to result in recurrence rates higher than
30% in GCT [12,14], whereas wide excision or segmental
tumor resection has been reported to produce much
lower recurrence rates of only 7% to 10%. These methods,
however, require complex bone and soft tissue repair and
reconstruction combined with revision surgery following
segmental resection of tumors. Thus, the high rate of
complications associated with these procedures necessi-
tates careful consideration of the risk of recurrence versus
maximum conservation of joint function [14,15].
Both primary and recurrent GCT of bone that are
classified as Enneking stage II are conventionally treated
with IC, and joint function surrounding the lesion is gen-
erally conserved to the highest possible extent [2,13,16].
In addition, IC has been widely recommended for the
treatment of cyst walls [2,12,16,17]. A retrospective ana-
lysis of 349 GCT cases demonstrated that IC significantly
reduced the rate of local recurrence of Enneking stage II
and partial stage III tumors to only 11.1% [17].
Although extended resection with conservation of the
bone cortex has been previously applied to treat locally
aggressive bone tumors in the extremities, the treatment
strategy proposed in this study mainly aimed to address
the problem of bone cortex reservation and conservation
of muscle (tendon) insertion. The clinical efficacy of ex-
tended resection with osteotomy, fenestration and con-
servation of muscle (tendon) insertion for treatment of
musculoskeletal tumors was investigated in patients
with locally aggressive musculoskeletal tumors including
ABC, CBT and GCT types. Rates recurrence and func-
tional restoration was assessed, providing potential prog-
nostic indicators that may aid in the clinical selection of
treatments for patients with locally aggressive musculo-
skeletal tumors.
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Participants
From 2004 through 2009, a total of 29 patients with
locally aggressive bone tumors of the extremities were
admitted to our hospital. Of these, only those exhibiting
tumors in the adjacent muscle (tendon) insertion of the
proximal extremities humerus or femur were included in
the present study. All included patients also exhibited an
Enneking stage of II. Patients were excluded if they
presented signs of malignant bone tumor according to
presurgical pathological examinations using fine needle
aspiration cytology or open biopsy.
For each included patient, bone cortex injury at the
lesion site was identified according to presurgical X-rays
and computed tomography (CT) scans, and the extent
of each lesion was identified using magnetic resonance
imaging (MRI).Surgical procedures
For all patients, brachial plexus anesthesia, lumbar anes-
thesia or general anesthesia was administered according
to the lesion site, and intravenous antibiotics were
administered 30 minutes prior to the surgery.
Each patient exhibiting a tumor of the proximal femur
was placed in the lateral position, and the insertion of
the abductor muscles (gluteus medius and minimus
muscles) and vastus lateralis muscle were exposed using
the lateral femoral approach (resection of biopsy tissues).
The insertion of the abductor muscle was maintained
intact, and osteotomy was performed via the greater tro-
chanter. The greater trochanter bone flap was uncovered
to expose lesions. Lesion tissues in the intertrochanteric
area and femoral neck were completely excised by scrap-
ing with a curet at various angles until the bursa wall
was reached, and the grooved region of the bony crest
was progressively removed with a high-speed drill. The
bursa wall is the inner wall or bony crest of the lesion,
representing the boundary of aggressive bone tumors.
Extended curettage requires thorough curettage of the
lesion tissue including the residual lesions in the
groove of the bursa to achieve complete excision of
the lesion.
The wound was cauterized using an argon gas knife
followed by normal saline washing. This procedure was
repeated three times. Femoral head and neck areas
beyond the reach of drill and knife techniques were fur-
ther treated by immersion in anhydrous ethanol for
15 min. Greater trochanter bone flap lesions on the
medial side and bony surface were treated similarly
(Figure 1B,C).
Each patient exhibiting a tumor of the proximal
humerus involving the intertubercular regions was
placed in the beach chair position, and an incision wasmade on the anterior third of the deltoid muscle prior to
resection of biopsy tissues. The rotator cuff insertion
was maintained intact, and osteotomy and fenestration
of the greater trochanter were performed. The muscle
bone flap was uncovered and lesions were excised using
the same method previously described for a tumor of
the proximal femur (Figure 2B,C).
After complete lesion curettage of tumors of either the
proximal femur or humerus, autogenous iliac cancellous
bone grafts and/or artificial bones were implanted im-
mediately after tumor resection in the same surgery
(stage I), rather than performing functional reconstruc-
tion in a separate operation. Bone cement augmentation
was routinely administered according to standard proto-
cols, particularly for patients with GCT. The proximal
femur was fixed with a titanium alloy plate. The prox-
imal humerus was fixed with anatomical humeral plates
and screws (Figures 1C and 2C).Postsurgical treatment
All patients were administered continuous intravenous
antibiotics for 24 h after surgery, and drainage tubes
were removed between 24 h and 48 h after surgery.
Postsurgical bracing was applied for four to six weeks
after surgery. Isometric muscle strength training of the
upper extremity was performed within 24 h after surgery
in most patients.Follow-up
All patients underwent follow-up after surgery for a
minimum of two years, and the time to full weight-
bearing was recorded for each patient. Periodic post-
surgical X-rays were performed to monitor bone healing
and track local recurrence. Imaging investigations, in-
cluding MRI, were used to confirm the recurrence of
lesions. During the follow-up period, CT and MRI were
performed only if deemed necessary due to abnormal
X-ray or functional assessments. Musculoskeletal tumors
were evaluated using the Enneking postoperative Mus-
culoskeletal Tumor Society score consisting of 30 total
possible points [1]. More than 70% of functional reco-
very was rated very good, 60% to 70% of recovery was
rated good, 50% to 60% of recovery was rated moderate
and less than 50% of recovery and amputation or death
was defined as poor.Statistical analysis
All data were analyzed using SPSS version 11.0 (SPSS
Inc., Chicago, IL, USA). Quantitative data for age, follow-
up duration and Enneking score data are expressed as
means ±SD.
Figure 1 Male patient, 19 years old with an aneurysmal bone cyst of the right proximal femur. (A) Presurgical X-ray and computed
tomography scan showing expansive cystic change in lesions in the right proximal femur, characterized by bony partition and thinning bone
cortex. Presurgical magnetic resonance imaging indicates that lesions exhibit unequal signal intensities with lobular changes. (B) Sketch map of
presurgical osteotomy line with osteotomy line (red) showing the greater trochanteric osteotomy and conserved insertion of the gluteus medius
and minimus muscles. (C) Intraoperative cauterization using an argon gas knife, anhydrous ethanol immersion, mixed bone graft with
autogenous bone, and artificial bone and reduction osteotomy. (D) X-ray at postsurgical month 24 revealing scattered calcifications on the graft
regions in the proximal femur without right hip pain. (E) Internal fixation removed after postsurgical month 36. X-ray revealing scattered
calcifications on the graft regions of the right hip, not significantly different from 24-month X-rays. No hip pain, normal weight-bearing, good
Enneking score and normal hip joint activity were reported.
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Demographic and clinical characteristics of included
patients
Of 29 patients treated, 15 presented with locally aggressive
tumors of the proximal femur (six patients) or humerus(nine patients), including eight men and seven women
with a mean age of 29 ±7.75 years (range, 18 to 42). An
ABC was diagnosed in seven patients including five
primary and two recurrent patients; CBT was diagnosed
in three patients; and GCT of bone was observed in five
Figure 2 Male patient, 19 years old, with chondroblastomas of the left proximal humerus. (A) Presurgical X-ray and computed
tomography scan showing expansive lesion growth in the proximal humerus and thinning of the bone cortex with bony septum and scattered
calcifications. Presurgical magnetic resonance imaging indicates T2-weighted images of tumors with inhomogeneous moderate signals and
scattered high signals complicated by edema and swelling of the surrounding soft tissues and the rotator cuff insertion adjacent to tumors. (B)
Sketch map of osteotomy of the greater tuberosity of the humerus showing osteotomy line (red) without injury to the subscapularis muscle,
infraspinous muscle, or insertion of the supraspinatus muscle. (C) Intraoperative treatment showing osteotomy and fenestration performed via
the greater tuberosity of the humerus and repeated cauterization with an argon gas knife. Autogenous and artificial bones were grafted. The
defective region of the aneurysm shell was then covered with autologous iliac bone containing cortical bone and treated with internal fixation
using an anatomical titanium alloy plate. (D) X-ray at postsurgical months 12 and 24 revealing no local recurrence. (E) Internal fixation was
removed after 24 months, resulting in normal left shoulder joint function, good Enneking score and no pain.
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in six patients, and tumors in the proximal femur were
found in nine patients (Table 1).
Proximal tumor and bone flap characteristics
In proximal femur tumors, most lesions were widely
distributed in the intertrochanteric areas and femur
neck, whereas proximal humerus tumors demonstrated
expansive growth in the humeral head, leading to com-
plications related to thinning bone cortex (Figures 1A
and 2A). No lesions penetrated the bone cortex, and thesurface of the articular cartilage remained intact in all
patients. Soft tissue edema without lesion infiltration
was observed in some cases. The bone flap with tendon
insertion was reduced in all cases, and small bone
defects were present in three patients following lesion
curettage.
After the tumor-shell bone was treated at the osteo-
tomy site, remaining small bone defects were covered
with sheets of autogenous iliac bone containing the
cortical bone. For the cases with GCT of bone, the
cavity was filled with bone cement, whereas the cavity of
Table 1 Characteristics and follow-up outcomes of 15 malignant musculoskeletal tumor patients
Gender Age
(years)







F 22 PH ABC IC+BG 37 - 29 Very good
M 19 PF ABC IC+BG 47 - 29 Very good
M 22 PH ABC IC+BG 36 - 29 Very good
F 27 PF ABC-R IC+BG 72 9 20 Good
M 21 PF ABC IC+BG 35 - 28 Very good
F 28 PF ABC-R IC+BG 45 - 29 Very good
M 27 PF CBT IC+BG 52 - 29 Very good
M 37 PF GCT IC+BC 46 - 29 Very good
M 19 PH CBT IC+BG 54 - 29 Very good
F 33 PF GCT IC+BC 43 - 28 Very good
F 38 PF GCT IC+BC 66 12 18a Moderatea
F 42 PH GCT IC+BC 53 - 29 Very good
M 38 PH CBT IC+BG 45 - 28 Very good
F 26 PH ABC IC+BG 25 - 19 Good



































ABC, aneurysmal bone cyst; ABC-R, recurrent aneurysmal bone cyst; BC, bone cement augmentation; BG, bone grafting; CBT, chondroblastoma; F, female; GCT,
giant-cell tumor of bone; IC, extended curettage; M, male; PH, proximal humerus; PF, proximal femur.
aPostsurgical scores and ratings after recurrence prior to secondary surgery; bmean ±SD (range); ctwo recurrent cases.
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and/or artificial bone grafts.
Postsurgical outcomes
The mean follow-up for all patients was 48 ±12.95
months (range, 25 to 72). During this period, no short-
term complications, such as hematoma or infection,
were observed. Furthermore, no long-term complica-
tions were observed, including pathological fractures,
local malignant transformation or distant metastasis.
Hip and joint activity gradually improved in patients
treated with bracing during the two weeks following sur-
gery, and all braces were removed between four and six
weeks after surgery. Most patients were able to initiate
isometric muscle strength training of the lower extrem-
ity within 24 h of surgery. Patients with femoral tumors
began partial weight-bearing and walking with the aid of
crutches at eight weeks, and all braces were removed by
postsurgical week 12.
One case of recurrent ABC was treated with curettage
of lesions with fenestration underneath the tuberosity
prior to IC with fenestration, resulting in hip pain within
six months of surgery. X-ray follow-up at postsurgical
month 12 revealed local bone graft absorption and slighthip pain in one patient, particularly when walking, that
persisted at postsurgical month 36. A second surgery
was advised. The patient thought that the hip pain was
tolerable and could normally walk with weight-bearing.
They did not undergo surgery and is currently being
followed-up.
Tumor recurrence
Local recurrence was observed in only two of fifteen pa-
tients (13%), including at nine months in one patient
with ABC of the proximal femur, who underwent a sec-
ond surgery and at 12 months in one patient with GCT.
The patient with recurring GCT underwent secondary
IC and bone cement augmentation. In the postsurgical
follow-up of the secondary surgeries, no additional re-
currence was reported. No local recurrence was detected
in any of the other 13 patients (Table 1).
Enneking scores
The mean Enneking score for all patients was 27 ±4.07
(18 to 29). The mean Enneking score for upper limbs
was 27 ±4.0 (18 to 29) and lower limbs was 27 ±4.3
(19 to 29). The lowest Enneking score was reported in
the patient with recurrent GCT. Except for this patient,
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good outcomes were reported in 80% of all patients
(12 out of 15) and 92% of patients (12 out of 13) without
recurrence (Table 1 and Figure 3).
Discussion
Patients with locally aggressive bone tumors such as
ABC, GCT and CBT were effectively treated with IC
(aggressive curettage) and high-speed drilling in combin-
ation with local adjuvant treatment measures, including
repeated cauterization of the cyst wall with an argon gas
knife and anhydrous alcohol immersion of deep regions.
These findings indicate that successful treatment of
locally aggressive bone tumors of Enneking stage II is
possible using these methods in practical clinical set-
tings. In the current study, the postsurgical recurrence
rate was 13.3% (two out of fifteen), much lower than the
postsurgical recurrence reported by several similar stud-
ies [3,11,12,14]. Therefore, IC may also effectively reduce
the postsurgical local recurrence of bone tumors of each
of these types.
Following IC treatment, satisfactory functional restor-
ation was achieved by all patients in the current study.
Using IC to treat CBT of bone, van der Geest et al. [11]
reported a postoperative Musculoskeletal Tumor Society
score of 93% (28 out of 30). In another study, IC for
treatment of 24 cases of CBT resulted in 87.5% very good
or good functional outcomes according to Enneking
scores (28 to 30) [ 8]. These treatments, however, did not
consider the importance of the muscle (tendon) insertion.
The current method allows for optimal conservation of
the bone context and avoids intraoperative damage to the
muscle (tendon) insertion. In the proximal femur, for
example, when the muscle insertion is protected during
surgery, traditional curettage can be performed with
fenestration underneath the tuberosity or on the posterior
femoral neck. The relatively small operating field and
complexity of the operation can result in incomplete
resectioning of tumors that widely involve the inter-Figure 3 Postsurgical follow-up of Enneking score and recurrence. En
(50 to 60); and poor (<50).trochanteric area and femoral neck. As a result, the risk of
postsurgical recurrence and osteonecrosis of the femoral
head is high.
The current study employed the surgical techniques
described by Ganz et al. [18], who suggested that lesion
exposure could be effectively achieved through greater
tuberosity osteotomy. This strategy not only protects the
muscle insertion but also provides a larger bone window
(about 5 cm × 3 cm) that increases the operating field
view. This strategy is optimal for achieving IC of lesions in
the intertrochanteric areas and femoral head (Figure 2B,C).
In the present study, imaging studies confirmed that the
anatomical structures of the rotator cuff insertion, curettage
of lesions with osteotomy and fenestration of the greater
tubercle of humerus achieved good exposure and con-
served the rotator cuff insertion, particularly in tumors
involving the proximal humerus (Figure 1B,C).
After complete treatment of the lesions using the
technique applied in the current study, bone fragments
on the muscle insertion were reduced by applying effect-
ive internal fixation. This IC method was designed to
conserve the muscle insertion integrity, thus enabling
reconstruction of bone-bone fixation but not tendon-bone
fixation following curettage. As a result, postsurgical
healing was primarily bone healing instead of tendon-
bone healing, which may produce more pronounced func-
tional impairments.
In the present study, postsurgical follow-up revealed
that about 93% of patients achieved very good or good
functional results according to Enneking scores, which
is similar or superior to the results of previous studies
[8,11,19]. Although these results indicate that the current
surgical strategy is superior for conservation of joint func-
tion and postsurgical rehabilitation in patients with bone
tumors of several types, it is important to consider that
this study also has some limitations. In particular, the
small number of patients and the use of only a single-
center patient population, which may not be representa-
tive of general patient populations due to the specializedneking score ratings: Very good (>70); good (60 to 70); moderate
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Furthermore, early functional exercise following surgery
and brace protection may have also impacted these posi-
tive findings. These techniques, however, merit further
study in larger cohorts and more varied patient popula-
tions due to their promising potential for dramatically
reducing recurrence rates and enhancing functional out-
comes. In addition, application of this technique for
secondary surgery for recurrent tumors should be more
carefully explored, though positive results can be expected
based on these preliminary findings.
Conclusions
Effective treatment of locally aggressive bone tumors
requires comprehensive analysis of the characteristics,
site and aggressiveness (Enneking stage) of tumors.
When determining an appropriate treatment strategy,
clinicians should carefully weigh the benefits of function
conservation in the proximal limb and joint with
complete tumor resection. The results of previous stud-
ies and the currently reported study suggest that
extended resection of tumors with osteotomy, fenestra-
tion and conservation of muscle (tendon) insertion can
be combined with effective internal fixation to reduce
postsurgical recurrence and protect joint function. Thus,
this strategy may be effective and feasible for treating
primary or recurrent locally aggressive bone tumors
classified as Enneking stage II in the proximal extrem-
ities, particularly those of the femur and humerus.
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for publication of this report and any accompanying
images.
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